Cochlear Overview

  • Year Founded
  • 1981

Year Founded

  • Status
  • Public

  • Employees
  • 4,500

Employees

  • Stock Symbol
  • COH

Stock Symbol

  • Investments
  • 16

  • Share Price
  • $103.03
  • (As of Friday Closing)

Cochlear General Information

Description

Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2026, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 1 University Avenue
  • Macquarie University
  • Sydney, New South Wales 2109
  • Australia
+61 (02)
Primary Industry
Surgical Devices
Other Industries
Therapeutic Devices
Other Devices and Supplies
Stock Exchange
ASX
Vertical(s)
Corporate Office
  • 1 University Avenue
  • Macquarie University
  • Sydney, New South Wales 2109
  • Australia
+61 (02)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cochlear Stock Performance

As of 13-Nov-2026, Cochlear’s stock price is $103.03. Its current market cap is $6.74B with 65.4M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$103.03 $104.67 $63.25 - $194.24 $6.74B 65.4M 589K $1.53

Cochlear Financials Summary

As of 30-Jun-2026, Cochlear has a trailing 12-month revenue of $1.59B.

In Thousands,
USD
TTM 30-Jun-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV 5,517,496 5,517,496 12,743,766 14,281,791
Revenue 1,590,332 1,590,332 1,516,030 1,465,074
EBITDA 217,861 217,861 393,517 366,924
Net Income 99,785 99,785 251,626 233,825
Total Assets 1,791,286 1,791,286 1,845,259 1,834,825
Total Debt 146,378 146,378 153,957 162,889
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cochlear Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cochlear‘s full profile, request access.

Request a free trial

Cochlear Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets con
Surgical Devices
Sydney, Australia
4,500 As of 2022

Smorum, Denmark
 

Marlborough, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cochlear Competitors (11)

One of Cochlear’s 11 competitors is Demant, a Corporation company based in Smorum, Denmark.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Demant Corporation Smorum, Denmark
Boston Scientific Corporation Marlborough, MA
Medtronic Corporation Minneapolis, MN
Zimmer Biomet Holdings Corporation Warsaw, IN
Globus Medical Formerly VC-backed Audubon, PA
You’re viewing 5 of 11 competitors. Get the full list »

Cochlear Patents

Cochlear Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026229769-A1 System and method for measuring skin flap thickness using signal absorption Pending 30-Apr-2025
WO-2026220242-A1 User directed frequency mapping Pending 16-Apr-2025
WO-2026210286-A1 Generating speech test materials with customizable linguistic characteristics Pending 01-Apr-2025
WO-2026202656-A1 Straightening mechanisms for implantable components Pending 27-Mar-2025
WO-2026202655-A1 Interactive aural language competency development Pending 26-Mar-2025 G10L15/26
To view Cochlear’s complete patent history, request access »

Cochlear Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cochlear Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cochlear‘s full profile, request access.

Request a free trial

Cochlear Investments & Acquisitions (16)

Cochlear’s most recent deal was a Later Stage VC with Epiminder for . The deal was made on 01-Feb-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Epiminder 01-Feb-2025 Later Stage VC Monitoring Equipment
Oticon Medical (Cochlear Implant Business) 21-May-2024 Merger/Acquisition Therapeutic Devices
Epiminder 15-Mar-2022 Later Stage VC Monitoring Equipment
Precisis 14-Oct-2021 Later Stage VC Therapeutic Devices
Seer Medical 26-Aug-2021 Early Stage VC Monitoring Equipment
You’re viewing 5 of 16 investments and acquisitions. Get the full list »

Cochlear ESG

Risk Overview

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Healthcare

Industry

Rank

Percentile

Medical Devices

Subindustry

Rank

Percentile

To view Cochlear’s complete esg history, request access »

Cochlear Exits (9)

Cochlear’s most recent exit was on 01-Feb-2025 from Epiminder. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Epiminder 01-Feb-2025 Completed
  • 2 buyers
Epiminder 15-Mar-2022 Completed
  • 4 buyers
Epiminder 23-Sep-2020 Completed
  • 4 buyers
Nyxoah 12-Feb-2020 Completed
  • 9 buyers
Epiminder 01-Jan-2019 Early Stage VC Completed
  • 4 buyers
You’re viewing 5 of 9 exits. Get the full list »

Cochlear Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Sycle (Business/Productivity Software) Lone Tree, CO 2001
Oticon Medical (Cochlear Implant Business) Vallauris, France

Cochlear FAQs

  • When was Cochlear founded?

    Cochlear was founded in 1981.

  • Where is Cochlear headquartered?

    Cochlear is headquartered in Sydney, Australia.

  • What is the size of Cochlear?

    Cochlear has 4,500 total employees.

  • What industry is Cochlear in?

    Cochlear’s primary industry is Surgical Devices.

  • Is Cochlear a private or public company?

    Cochlear is a Public company.

  • What is Cochlear’s stock symbol?

    The ticker symbol for Cochlear is COH.

  • What is the current stock price of Cochlear?

    As of 13-Nov-2026 the stock price of Cochlear is $103.03.

  • What is the current market cap of Cochlear?

    The current market capitalization of Cochlear is $6.74B.

  • What is Cochlear’s current revenue?

    The trailing twelve month revenue for Cochlear is $1.59B.

  • Who are Cochlear’s competitors?

    Demant, Boston Scientific, Medtronic, Zimmer Biomet Holdings, and Globus Medical are some of the 11 competitors of Cochlear.

  • What is Cochlear’s annual earnings per share (EPS)?

    Cochlear’s EPS for 12 months was $1.53.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process